BRAINSTORM CELL THERAPEUTICS
brainstorm-cell.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Brainstorm Cell Therapeutics faces cash challenges with only $15,000 in cash as of March 31, 2026, while managing multiple legal proceedings.
The current 10-Q filing reflects a significant decline in cash and cash equivalents, dropping from $1,644,000 in March 2025 to $15,000 in March 2026, indicating worsening liquidity. Business operations remain consistent in their focus on developing autologous cellular therapies for neurodegenerative diseases but face ongoing legal scrutiny from securities class actions. Overall financial stability is decreasing as operating costs continue to be high without revenue generation.
Key figures from the filing
- ▸Total current assets decreased from $307,000 at December 31, 2025, to $184,000 at March 31, 2026.
- ▸Cash and cash equivalents significantly declined from $29,000 in 2025 to $15,000 in 2026, highlighting liquidity challenges.
- ▸Other accounts receivable increased, potentially indicating improved revenue recognition or collections from previous periods.
Red Flags Detected (2)
Severe decrease in cash reserves raises operational sustainability questions.
Ongoing litigation risks related to multiple class actions could impede management focus.
Key Takeaways
Investors should closely monitor liquidity levels and the impact of ongoing legal risks.
With no revenue generation, the company must find a way to stabilize its cash flow to sustain operations.
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.